Mounjaro®
Starting from £179.99/mo
Start journey Learn moreWeaning off Wegovy without gaining weight is possible, but it takes planning. Semaglutide suppresses appetite actively while you take it; when you stop, that suppression fades and hunger tends to return gradually. The research suggests that most people regain a meaningful portion of lost weight in the year or two after stopping, though the picture varies considerably by individual. These are prescription-only medicines, and any decision to stop, reduce doses, or switch treatment should be made with your prescriber — not unilaterally. The good news is that the transition goes better with preparation than without it, and this page sets out the factors that matter most.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The reason weight can return after stopping semaglutide is not a willpower failure. Wegovy works by activating GLP-1 receptors that regulate appetite and slow gastric emptying, making you feel full on less food. The medicine is doing the physiological work. When you stop it, those pathways return to their pre-treatment state, and for many people that means hunger rises back to previous levels relatively quickly.
Clinical trial follow-up data make this clear. In the STEP 1 extension, participants who stopped semaglutide 2.4mg after 68 weeks regained, on average, around two-thirds of their lost weight within the following year, as reported in the original STEP 1 paper in the New England Journal of Medicine and subsequent follow-up publications. That statistic is not a reason to stay on the medicine indefinitely against your own wishes; it is a reason to treat the stopping decision as a clinical conversation, not a quiet self-managed withdrawal.
Understanding this dynamic is actually useful. If you know hunger will return, you can prepare for it, and if you want a detailed look at whether it is possible to come off Wegovy without gaining weight, that question is explored fully on a dedicated page. The patients who fare best after stopping are those who used the period of reduced appetite to build sustainable eating patterns, not just to eat less, but to restructure what they eat and when. By the time you wean off Wegovy, those habits should be close to automatic. If they are not quite there yet, that is worth discussing with your prescriber before you reduce your dose.
Abrupt cessation tends to produce a sharper return of appetite than a slow step-down. There is no single published protocol for weaning off semaglutide, but the logic of gradual dose reduction is straightforward: lower doses produce proportionally less appetite suppression, so stepping down gives your system (and your habits) time to adapt before you are managing entirely without the medicine.
In practice, your prescriber might suggest holding at a lower maintenance dose for several weeks before stopping entirely, or spacing out your injections differently. What they will not do is issue a one-size approach, because the right path depends on how long you have been on Wegovy, which dose you reached, how much weight you have lost, and what your underlying weight-related health conditions are.
This is also the moment to think honestly about whether stopping is the right move right now. NHS England's guidance on weight-management injections describes obesity as a chronic condition, which means that, for some people, long-term treatment is clinically appropriate, in the same way antihypertensives are not usually stopped once blood pressure is controlled. If the reason you are considering stopping is cost or side effects rather than having reached your goals, those conversations are worth having first. You can read more about how Wegovy works and what the treatment arc typically looks like before deciding.
Preparation is the main lever you have. The three areas that make the most difference are nutrition structure, physical activity, and a plan for managing returning hunger.
On nutrition: protein and fibre are the most useful dietary factors when semaglutide is no longer doing the satiety work for you. Protein takes more energy to process than carbohydrates or fat and tends to sustain fullness longer. Meals with adequate protein (think eggs, fish, poultry, legumes, Greek-style yogurt) reduce the likelihood that returning appetite will translate into meaningfully higher calorie intake. The NHS's guidance on maintaining a healthy weight covers the evidence-based basics clearly.
On activity: building consistent strength or resistance training during treatment is probably the highest-return action for protecting against post-stopping regain. Muscle tissue raises resting metabolism and uses energy differently from fat tissue. Many people find that Wegovy gives them the capacity to exercise more and recover better than before. That window is worth using purposefully.
On hunger management: identify your personal hunger patterns. What time of day does appetite peak? What food environments lead you to eat beyond what you intended? Having answers ready before appetite returns means you are responding with a plan rather than reacting in the moment.
If you are thinking about what stopping might mean for you more broadly (or whether weaning is even the right direction versus a dose adjustment) it is worth reading about maintaining weight without Wegovy as a parallel resource, and considering what support you will have in place. The Wegovy weight-loss time frame page also helps set realistic expectations for what the trajectory actually looks like. Treatment decisions are ultimately made between you and a clinical professional, and the prescribers at our clinical team carry out that review personally before any repeat or change.
If you have already stopped Wegovy and weight is returning, you are not in an unusual situation. Regain does not mean the treatment failed; it often means the biological drive that made weight management difficult in the first place has reasserted itself without the medicine's support. The question at that point is what the right next step is, and it is worth framing it as a clinical question rather than a personal one.
Options might include restarting at a lower dose, switching to an alternative licensed treatment such as tirzepatide (Mounjaro), or reinforcing lifestyle support with professional input. Weight gain during or after Wegovy is explored in more detail on a dedicated page. If you did not start treatment through a service that reviews your clinical picture before every repeat, that is also worth reconsidering. Every repeat order at nume includes a clinical review by a GPhC-registered Independent Prescriber, the same rigour applies whether you are continuing, adjusting or stopping. If restarting sounds right, the process for getting Wegovy through a regulated UK pharmacy is straightforward and starts with a free consultation.
Speak to our prescribers if you are at the weaning stage and want a clinical view on how to do it sensibly. It is the kind of conversation that is better had before you stop than after.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.